Official websites use. Share sensitive information only on official, secure websites. Email: aalhendy bsd. Qiwei Yang, Ph.
Email: yangq bsd. For commercial re-use, please contact journals. Uterine fibroids are benign monoclonal neoplasms of the myometrium, representing the most common tumors in women worldwide. To date, no long-term or noninvasive treatment option exists for hormone-dependent uterine fibroids, due to the limited knowledge about the molecular mechanisms underlying the initiation and development of uterine fibroids.
This paper comprehensively summarizes the recent research advances on uterine fibroids, focusing on risk factors, development origin, pathogenetic mechanisms, and treatment options. Additionally, we describe the current treatment interventions for uterine fibroids.
Finally, future perspectives on uterine fibroids studies are summarized. Deeper mechanistic insights into tumor etiology and the complexity of uterine fibroids can contribute to the progress of newer targeted therapies.
Keywords: uterine fibroids, developmental origin, genetic instability, reprogramming, epigenetics pathways, novel treatment, future directions. Developmental exposure to EDCs in early life reprograms myometrial stem cells, thus increasing the risk of uterine fibroids development.
